| Acute myeloid leukemia with the t (8; 21) translocation: clinical consequences and biological implications H Reikvam, KJ Hatfield, AO Kittang, R Hovland, Ø Bruserud BioMed Research International 2011, 2011 | 156 | 2011 |
| Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells Ø Bruserud, A Ryningen, AM Olsnes, L Stordrange, AM Øyan, KH Kalland, ... Haematologica 92 (3), 332-341, 2007 | 144 | 2007 |
| Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation L Cassetta, K Bruderek, J Skrzeczynska-Moncznik, O Osiecka, X Hu, ... Journal for immunotherapy of cancer 8 (2), 2020 | 132 | 2020 |
| Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome AO Kittang, S Kordasti, KE Sand, B Costantini, AM Kramer, ... Oncoimmunology 5 (2), e1062208, 2016 | 113 | 2016 |
| The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications AO Kittang, K Hatfield, K Sand, H Reikvam, Ø Bruserud The Chemokine System in Experimental and Clinical Hematology, 149-172, 2010 | 82 | 2010 |
| Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies KJ Hatfield, AM Olsnes, BT Gjertsen, O Bruserud Current cancer drug targets 5 (4), 229-248, 2005 | 78 | 2005 |
| Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up P Baliakas, B Tesi, U Wartiovaara-Kautto, A Stray-Pedersen, LS Friis, ... Hemasphere 3 (6), e321, 2019 | 77 | 2019 |
| The chemokine system in experimental and clinical hematology Ø Bruserud, AO Kittang The Chemokine System in Experimental and Clinical Hematology, 3-12, 2010 | 73 | 2010 |
| The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity E Ersvaer, AO Kittang, P Hampson, K Sand, BT Gjertsen, JM Lord, ... Toxins 2 (1), 174-194, 2010 | 72 | 2010 |
| Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation H Reikvam, KJ Hatfield, AM Øyan, KH Kalland, AO Kittang, Ø Bruserud European journal of haematology 84 (3), 239-251, 2010 | 66 | 2010 |
| Nuclear factor-κB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia H Reikvam, AM Olsnes, BT Gjertsen, E Ersvar, O Bruserud Critical Reviews™ in Oncogenesis 15 (1-2), 2009 | 66 | 2009 |
| Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low-and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial M Tobiasson, I Dybedahl, MS Holm, M Karimi, L Brandefors, H Garelius, ... Blood Cancer Journal 4 (3), e189-e189, 2014 | 63 | 2014 |
| T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 … AM Olsnes, D Motorin, A Ryningen, AY Zaritskey, Ø Bruserud Cancer Immunology, Immunotherapy 55, 830-840, 2006 | 55 | 2006 |
| The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia H Fredly, E Ersvær, AO Kittang, G Tsykunova, BT Gjertsen, Ø Bruserud Clinical epigenetics 5, 1-15, 2013 | 54 | 2013 |
| Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and … H Reikvam, KJ Hatfield, P Lassalle, A Olsnes Kittang, E Ersvaer, ... Expert opinion on investigational drugs 19 (2), 169-183, 2010 | 49 | 2010 |
| Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets N Bizymi, S Bjelica, AO Kittang, S Mojsilovic, M Velegraki, C Pontikoglou, ... HemaSphere 3 (1), e168, 2019 | 48 | 2019 |
| Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia‐associated antigen associated with autoantibody … E Ersvaer, JY Zhang, E McCormack, A Olsnes, N Ånensen, E M. Tan, ... European Journal of Haematology 79 (3), 210-225, 2007 | 44 | 2007 |
| The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis … H Reikvam, H Fredly, AO Kittang, Ø Bruserud Toxins 5 (2), 336-362, 2013 | 41 | 2013 |
| The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target? GK Melve, E Ersvaer, AO Kittang, Ø Bruserud Expert Review of Hematology 4 (5), 563-576, 2011 | 40 | 2011 |
| The protein kinase C agonist PEP005 increases NF‐κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells AM Olsnes, E Ersvaer, A Ryningen, K Paulsen, P Hampson, JM Lord, ... British journal of haematology 145 (6), 761-774, 2009 | 37 | 2009 |
Bjorn T. GjertsenProfessor of Hematology, University of BergenE-mail megerősítve itt: uib.no
